CTLA4 and pancreatic ductal adenocarcinoma: This anti-CSF1 treatment sensitised resistant pancreatic ductal adenocarcinoma (PDAC) towards treatment with checkpoint inhibitors (anti-PD1 or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4)).